REGN15505+Cemiplimab
Preclinical
RegeneronREGN15505+Cemiplimab is one of 8 therapeutic programs targeting Metastatic Castration-resistant Prostate Cancer, mCRPC. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Metastatic Castration-Resistant Prostate Cancer, Mcrpc
#DrugCompanyPhaseTrials
1Libtayo
RegeneronPreclinical
Xaluritamig
AmgenPhase 1
AAA617
NovartisPhase 2
Fludara
SanofiPreclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
REGN5678
RegeneronPreclinical
Adi-212
AAdicet Therapeutics
Preclinical
REGN15505+Cemiplimab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for REGN15505+Cemiplimab. EMBL-EBI & Wellcome Sanger Institute.
- [3]